Attovia Therapeutics, Inc. Stock: price and insider trades · United States

Attovia Therapeutics, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 48 filings came from 8 insiders.

The record shows 7 purchases on the open market worth €36.4M, made by 5 insiders, against 22 sales worth €1.9M by 1 insider. On balance, insiders were net buyers of €34.5M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 4 major shareholders. Frazier Life Sciences XI, L.P. filed the largest purchase, €8.6M, on 6 August 2026, which represents 1.2% of the company's market value.

In all, 6 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (13 August 2026) now reads 65 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 8 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 48 filings, this issuer sits above that mark. Since 2026, the database holds 7 purchases and 22 sales by insiders of the company.

Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.